Clinical Evaluation of Patients With X-linked Retinoschisis

Inclusion Criteria: Main Study: * Clinical diagnosis consistent with XLRS * Documented disease causing RS1 mutation * 7 years of age or older * Able to provide informed consent/assent * Male CAI sub-study: • Presence of maculoschisis Exclusion Criteria: Main Study: • Other eye diseases that might affect the results (e.g. history of retinal detachment, glaucoma, cataracts that prohibit imaging, or any other eye pathology that in the opinion of the investigator would preclude enrollment) CAI Sub-study: Exclusion Criteria * Already being treated with CAIs * Previous documented failure to respond to CAI treatment Any drug-specific contraindication/precaution listed below (from www.micromedex.com): Topical Eye Drop Dorzolamide Hydrochloride Contraindications: • hypersensitivity to dorzolamide products, including sulfa allergies Precautions: * dorzolamide is a sulfonamide that is absorbed systemically, sulfonamide hypersensitivity reactions may occur * angle-closure glaucoma * concomitant use of oral carbonic-anhydrase inhibitors * conjunctivitis and lid reactions reported with chronic administration * moderate to severe renal (CrCl less than 30 mL/min) or hepatic insufficiency * ocular infection or inflammation * recent ocular surgery Topical Eye Drop Brinzolamide Contraindications: • hypersensitivity to any component of the product, including sulfa allergies Precautions: * concomitant use of oral carbonic anhydrase inhibitors is not recommended * contact lens…